These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9468586)

  • 41. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
    Bograd AJ; Suzuki K; Vertes E; Colovos C; Morales EA; Sadelain M; Adusumilli PS
    Cancer Immunol Immunother; 2011 Nov; 60(11):1509-27. PubMed ID: 21913025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy.
    Sterman DH; Recio A; Vachani A; Sun J; Cheung L; DeLong P; Amin KM; Litzky LA; Wilson JM; Kaiser LR; Albelda SM
    Clin Cancer Res; 2005 Oct; 11(20):7444-53. PubMed ID: 16243818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of malignant pleural mesothelioma].
    Köksal D; Beder S
    Tuberk Toraks; 2003; 51(3):310-9. PubMed ID: 15143412
    [No Abstract]   [Full Text] [Related]  

  • 44. Malignant mesothelioma 2008.
    Zervos MD; Bizekis C; Pass HI
    Curr Opin Pulm Med; 2008 Jul; 14(4):303-9. PubMed ID: 18520263
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
    Donskov F
    Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact.
    Alì G; Boldrini L; Lucchi M; Picchi A; Dell'Omodarme M; Prati MC; Mussi A; Corsi V; Fontanini G
    Br J Cancer; 2009 Dec; 101(11):1869-75. PubMed ID: 19935800
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, feasibility and therapeutic activity of intrapleural autologous lymphocyte conditioned medium followed by systemic recombinant interleukin-2 and interferon-alpha in a patient with malignant pleural mesothelioma.
    Duensing S; Hamm H; Ganser A; Atzpodien J
    Cancer Biother Radiopharm; 1997 Jun; 12(3):141-2. PubMed ID: 10851459
    [No Abstract]   [Full Text] [Related]  

  • 49. Gene therapy for malignant pleural mesothelioma.
    Sterman DH; Kaiser LR; Albelda SM
    Hematol Oncol Clin North Am; 1998 Jun; 12(3):553-68. PubMed ID: 9684098
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mesothelioma and local immunotherapy.
    Sone S; Tsubura E
    Ann Intern Med; 1978 Apr; 88(4):575. PubMed ID: 345909
    [No Abstract]   [Full Text] [Related]  

  • 51. Immune function and survival in pleural mesothelioma.
    Law MR; Smith MJ; Millband C; Haslam PL; Hodson ME
    Clin Exp Immunol; 1985 Jul; 61(1):214-5. PubMed ID: 4042419
    [No Abstract]   [Full Text] [Related]  

  • 52. Molecular pathobiology and immunology of malignant mesothelioma.
    Bielefeldt-Ohmann H; Jarnicki AG; Fitzpatrick DR
    J Pathol; 1996 Apr; 178(4):369-78. PubMed ID: 8691313
    [No Abstract]   [Full Text] [Related]  

  • 53. Nursing guidelines and discharge planning for patients receiving recombinant interleukin-2.
    Caliendo G; Joyce D; Altmiller MC
    Semin Oncol Nurs; 1993 Aug; 9(3 Suppl 1):25-31. PubMed ID: 8210791
    [No Abstract]   [Full Text] [Related]  

  • 54. Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.
    Upham JW; Garlepp MJ; Musk AW; Robinson BW
    Thorax; 1995 Aug; 50(8):887-93. PubMed ID: 7570443
    [No Abstract]   [Full Text] [Related]  

  • 55. Context-dependent effects of IL-2 rewire immunity into distinct cellular circuits.
    Whyte CE; Singh K; Burton OT; Aloulou M; Kouser L; Veiga RV; Dashwood A; Okkenhaug H; Benadda S; Moudra A; Bricard O; Lienart S; Bielefeld P; Roca CP; Naranjo-Galindo FJ; Lombard-Vadnais F; Junius S; Bending D; Ono MM; Hochepied T; Halim TYF; Schlenner S; Lesage S; Dooley J; Liston A
    J Exp Med; 2022 Jul; 219(7):. PubMed ID: 35699942
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of interleukin-2 for the treatment of malignant mesothelioma.
    Nano R; Capelli E; Civallero M; Terzuolo G; Volpini E; Nascimbene C; Cremaschi P
    Oncol Rep; 1998; 5(2):489-92. PubMed ID: 9468586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?
    Lucchi M; Picchi A; Alí G; Chella A; Guglielmi G; Cristaudo A; Fontanini G; Mussi A
    Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):572-6. PubMed ID: 20053697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.
    Ampollini L; Soltermann A; Felley-Bosco E; Lardinois D; Arni S; Speck RF; Weder W; Opitz I
    Eur J Cardiothorac Surg; 2009 Mar; 35(3):457-62. PubMed ID: 19162494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Immunotherapy and malignant mesothelioma: clinical perspectives].
    Grégoire M; Ebstein F
    Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
    Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.